Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T R Wilson

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Oncogenesis|December 25, 2013
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerL-Y Huw, C O'Brien, A Pandita, et al.
Breast Cancer Research and Treatment|August 9, 2014
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancerL M Arthur, A K Turnbull, L Renshaw, et al.
Peptides|June 28, 2005
Discovery of an MIT-like atracotoxin family: spider venom peptides that share sequence homology but not pharmacological properties with AVIT family proteinsSuping Wen, David T R Wilson, Sanjaya Kuruppu, et al.
Cell Death and Differentiation|June 23, 2009
Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencingT R Wilson, K M Redmond, K M McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerV Diéras, M Campone, D A Yardley, et al.
NPJ Precision Oncology|July 21, 2021
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
NPJ Precision Oncology|September 18, 2021
Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2020
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trialS Dent, J Cortés, Y-H Im, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2020
Australian funnel-web spiders evolved human-lethal δ-hexatoxins for defense against vertebrate predatorsVolker Herzig, Kartik Sunagar, David T R Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancersD Fumagalli, T R Wilson, R Salgado, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Oncogenesis|December 25, 2013
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerL-Y Huw, C O'Brien, A Pandita, et al.
Breast Cancer Research and Treatment|August 9, 2014
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancerL M Arthur, A K Turnbull, L Renshaw, et al.
Peptides|June 28, 2005
Discovery of an MIT-like atracotoxin family: spider venom peptides that share sequence homology but not pharmacological properties with AVIT family proteinsSuping Wen, David T R Wilson, Sanjaya Kuruppu, et al.
Cell Death and Differentiation|June 23, 2009
Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencingT R Wilson, K M Redmond, K M McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerV Diéras, M Campone, D A Yardley, et al.
NPJ Precision Oncology|July 21, 2021
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
NPJ Precision Oncology|September 18, 2021
Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2020
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trialS Dent, J Cortés, Y-H Im, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2020
Australian funnel-web spiders evolved human-lethal δ-hexatoxins for defense against vertebrate predatorsVolker Herzig, Kartik Sunagar, David T R Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancersD Fumagalli, T R Wilson, R Salgado, et al.
Pageof 4